Home › Renal Insufficiency › NCT06620523
Prevent Cardiac Surgery Associated AKI Trial
Efficacy of Mitochondrial Directed Therapy in Prevention of Cardiac Surgery Associated AKI Prevent Cardiac Surgery Associated AKI Trial (Prevent CSA-AKI Trial)
Who can join
Ages 18 to 70 · All sexes
Full eligibility criteria
Inclusion Criteria: * Adult 18-70 years of age * Undergoing elective CPB (Cardiopulmonary Bypass) surgery * Baseline GFR (Glomerular Filtration Rate) ≥45 ml/min Exclusion Criteria: * GFR (Glomerular Filtration Rate) \<45 ml/min * Solitary kidney * Status post-kidney transplant * Pregnant women * Allergy to CoQ10 * Allergy to Glutathione * Allergy to Cellulose
About the study
Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.
What is being tested
- CoQ10 1200 mg orally with Glutathione 1000 mg orally (drug)
- Group B: Placebo CoQ10 orally and Placebo Glutathione orally (drug)
Sponsor: George Washington University · Participants: 242 · Started: Jul 18, 2024
Contact the study team
- Eduard Shaykhinurov, MS · Phone: 2028234259
Official record on ClinicalTrials.gov — NCT06620523
Locations in the U.S.
| District of Columbia | George Washington University Hospital, Washington D.C. |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.